Pharmaceuticals News and Research

RSS

Rigel reports net loss of $25.6 million in first quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.

7 May 2013

Perrigo net sales increase 18% to $920M in third quarter 2013

Perrigo Company today announced results for its third quarter ended March 30, 2013.Perrigo's Chairman and CEO Joseph C. Papa commented, "We are very pleased with our performance, as the team delivered all-time record quarterly revenue and adjusted diluted earnings per share.

7 May 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

7 May 2013

Nuvo Research intends to proceed with its proposed share consolidation

Nuvo Research Inc. (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012, on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.

7 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Aptiv Solutions participates in 'Practice Adaptive Clinical Trials’ conference at Tokyo University

Aptiv Solutions, a biopharmaceutical and medical device development services company and pioneer in adaptive clinical trial design, simulation and execution, announces its participation in a prestigious conference on adaptive clinical trials, held at the University of Tokyo on May 10th 2013.

7 May 2013

Biocryst reports financial results for first quarter 2013

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2013.

7 May 2013

Akorn reports record consolidated revenue of $73.9 million in first quarter 2013

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for its first quarter ended March 31, 2013.

7 May 2013

New Process Analytical Technology for pharmaceutical and chemical manufacturing industries

Process Analytical Technology (PAT) is quickly becoming an integral component in the pharmaceutical and chemical manufacturing industries. Utilizing a low latency network of powerful chemometric instruments, multivariate data analysis software, process control tools, and a central SQL database, PAT provides pharmaceutical and biopharmaceutical companies an edge over their competitors.

From Thermo Fisher Scientific Inc. 7 May 2013

Entremed reports patent issuance for its lead drug candidate ENMD-2076

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.

7 May 2013

Study; Media reports about supposedly hazardous substances may trigger nocebo effect in some people

Media reports about substances that are supposedly hazardous to health may cause suggestible people to develop symptoms of a disease even though there is no objective reason for doing so.

7 May 2013

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

7 May 2013

Researchers publish new Canadian guidelines for diagnosis and treatment of fibromyalgia

Physicians from the McGill University Health Centre (MUHC) and the University of Calgary have published a review article in the CMAJ (Canadian Medical Association Journal) to help family doctors diagnose and treat fibromyalgia.

7 May 2013

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's.

7 May 2013

The race to make abuse-proof painkillers; states lead on compounding pharmacy regulation

Developments in pharmaceuticals make headlines: the race to make painkillers that are difficult to abuse, state action on regulating compounding pharmacies and the difference in how much different Americans pay for prescriptions.

7 May 2013

34% of all adverts for antidepressants are misleading by industry's self-regulation system

The new feature of the antidepressant drugs of the 1990s was that they had milder side-effects than their predecessors. Combined with aggressive marketing, this meant that annual sales in Sweden increased from just under EUR 18 million to over EUR 100 million in the space of just a few years.

6 May 2013

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.

6 May 2013

First Edition: May 6, 2013

Kaiser Health News staff writer Phil Galewitz, working in collaboration with The Washington Post, reports: "Florida is on course to spend $6 million to reach out to nearly 4 million uninsured people and help them sign up for coverage in the federal health law's online marketplace this fall.

6 May 2013

Highlights: New health care oversight laws in Md.; Texas hospitals negotiate over uncompensated care payments; Colo. considers psychiatric hospital for homeless

Maryland Gov. Martin O'Malley signed three laws Thursday that will give more protection for patients. The measures provide more state oversight of cosmetic surgery centers, pharmacies that make sterile medications and staffing agencies that find temporary jobs for health care professionals (Sun, 5/2).

4 May 2013

Researchers issue statement regarding use of unproven stem cell therapies

An international group of leading stem cell researchers has issued a statement that specifies concerns about the development and use of unproven stem cell therapies.

4 May 2013

Pharmaceuticals News and Research

Rigel reports net loss of $25.6 million in first quarter 2013

Perrigo net sales increase 18% to $920M in third quarter 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Nuvo Research intends to proceed with its proposed share consolidation

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Aptiv Solutions participates in 'Practice Adaptive Clinical Trials’ conference at Tokyo University

Biocryst reports financial results for first quarter 2013

Akorn reports record consolidated revenue of $73.9 million in first quarter 2013

New Process Analytical Technology for pharmaceutical and chemical manufacturing industries

Entremed reports patent issuance for its lead drug candidate ENMD-2076

Study; Media reports about supposedly hazardous substances may trigger nocebo effect in some people

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Researchers publish new Canadian guidelines for diagnosis and treatment of fibromyalgia

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

The race to make abuse-proof painkillers; states lead on compounding pharmacy regulation

34% of all adverts for antidepressants are misleading by industry's self-regulation system

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

First Edition: May 6, 2013

Highlights: New health care oversight laws in Md.; Texas hospitals negotiate over uncompensated care payments; Colo. considers psychiatric hospital for homeless

Researchers issue statement regarding use of unproven stem cell therapies

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence